Chemours Co
No SEC Form 4 filings for $CC in the last 30 days.
Chemours (NYSE: CC) shares fell 18.7% after the company reported Q2 results. Revenue edged down and adjusted EPS fell 31% to $0.42, missing expectations. Lower Optane refrigerant sales and the prior wind-down of the SPS Capstone business weighed on results. Chemours still forecasts full-year growth of 1% to 5%.
Chemours (NYSE: CC) reported Q2 2026 results: net sales about $1.6B, roughly flat year over year. Net loss attributable to Chemours was $274M ($1.81 per diluted share) versus $380M ($2.53) a year earlier. Adjusted net income was $64M ($0.42) and adjusted EBITDA $247M. Free cash flow rose 128% and net leverage fell to 4.4x. Chemours cited TiO2 pricing actions and APM Performance Solutions growth.
Chemours Co (CC) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 cc-ex99_1.htm EX-99.1 EX-99.1 EXHIBIT 99.1 The Chemours Company Reports Second Quarter Results Wilmington, Del., August 4, 2026 – The Chemours Company (“Chemours” or “the Company”) (NYSE: CC), a global chemistry company with leading market positions in Thermal & Special
Over the past 7 days, alphai's AI scored 3 news stories mentioning CC (Chemours Co). Coverage has skewed bearish: 0 bullish, 2 neutral, and 1 bearish.
Recent CC coverage spans earnings, market movers and financial news.
The selloff is tied to weaker Optane refrigerant sales due to supply-chain inventory overhang and the prior wind-down of SPS Capstone.
The print is a mixed fundamental update: cash generation and leverage improved, but adjusted EBITDA and APM profitability fell on outage and line-closure effects.
The 8-K provides fresh quarterly datapoints on profitability, cash generation, leverage, and segment drivers, which can reset near-term expectations.
This is a scheduled earnings timing update, setting a near-term catalyst window for CC options and positioning.
The trade hinges on whether Chemours can show margin stabilization and cash-flow clarity after the $450M PFAS settlement and March debt offering.
alphai scores every news story that mentions CC with an AI model for sentiment and relevance, and aggregates insider trades from Chemours Co's SEC EDGAR Form 4 filings. Figures refresh continuously.
Chemours (NYSE: CC) shares fell 18.7% after the company reported Q2 results. Revenue edged down and adjusted EPS fell 31% to $0.42, missing expectations. Lower Optane refrigerant sales and the prior wind-down of the SPS Capstone business weighed on results. Chemours still forecasts full-year growth of 1% to 5%.
4 min readChemours (NYSE: CC) reported Q2 2026 results: net sales about $1.6B, roughly flat year over year. Net loss attributable to Chemours was $274M ($1.81 per diluted share) versus $380M ($2.53) a year earlier. Adjusted net income was $64M ($0.42) and adjusted EBITDA $247M. Free cash flow rose 128% and net leverage fell to 4.4x. Chemours cited TiO2 pricing actions and APM Performance Solutions growth.
7 min readChemours Co (CC) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 cc-ex99_1.htm EX-99.1 EX-99.1 EXHIBIT 99.1 The Chemours Company Reports Second Quarter Results Wilmington, Del., August 4, 2026 – The Chemours Company (“Chemours” or “the Company”) (NYSE: CC), a global chemistry company with leading market positions in Thermal & Special
6 min readChemours (NYSE: CC) said it will release Q2 2026 financial results after market close on Aug. 4, 2026, and hold a public webcast conference call at 8:00 a.m. EDT on Aug. 5. The webcast, slides, and replay will be available via Chemours’ Investor Relations “Events and Presentations” page, according to the company.
1 min readChemours Co. is set to report Q2 results Thursday. Analysts expect EPS of 50 cents on revenue of $1.66B, versus $0.05 EPS and $1.4B revenue in Q1. Forecasts imply sequential revenue growth of 18.6% and a margin focus. The company also faces a $450M EPA PFAS settlement and recent $700M debt offering.
4 min readBMO Capital, in a July 6 report, reiterated a Buy rating on Chemours (NYSE:CC) and set a $26 price target, near the $25 median of 11 analysts. The stock trades about 11% below the lowest target ($21). Mizuho Securities cut its target from $30 to $25 on July 1, citing lower oil prices and sector outlook changes.
3 min readThe article lists 8 “undervalued growth” stocks screened by market cap (at least $2B), forward P/E under 15x, and expected earnings growth above 30% over 5 years, ranked by forward P/E. It cites Edward Jones strategist Angelo Kourkafas on valuation and earnings delivery. Examples: Chemours (CC) has BMO Buy $26 target and Mizuho Outperform $25; Phillips 66 (PSX) has Wells Fargo Buy $201 target.
7 min readNew York Attorney General Letitia James sued 3M, DuPont, Chemours, Corteva and EIDP over alleged PFAS (“forever chemicals”) contamination. The complaint says the firms knew since decades-old research that PFAS were toxic but concealed risks, continued selling PFAS products, and allegedly misled consumers. New York seeks cleanup funding, consumer warnings, advertising changes, and damages and penalties.
3 min read3M (MMM) and DuPont (DD) shares fell after New York Attorney General Letitia James filed a lawsuit over alleged PFAS (“forever chemicals”) pollution. The complaint says the companies manufactured and sold PFAS products while knowing risks and failing to warn. The AG seeks cleanup funding, sales halts, advertising changes, and damages. NYDEC and NYDOH assisted.
4 min readChemours Co. (NYSE:CC) options activity rose to 5,376 contracts by 2:51 p.m. ET Thursday, per exchange data compiled by Bloomberg. Calls were 4,348 and puts 1,028. The July 24, 2026 $22 call led with 2,619 contracts. CC shares fell 5.21% to $19.09.
2 min read
